Related Experiment Video
Updated: Jul 24, 2025
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
Nanotechnological Advancements for the Theranostic Intervention in Anaplastic Thyroid Cancer: Current Perspectives
Sai Swetha Uppalapati1, Lahanya Guha2, Hemant Kumar2
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Ahmedabad, India.
Abstract:
Anaplastic thyroid cancer is the rarest, most aggressive, and undifferentiated class of thyroid cancer, accounting for nearly forty percent of all thyroid cancer-related deaths. It is caused by alterations in many cellular pathways like MAPK, PI3K/AKT/mTOR, ALK, Wnt activation, and TP53 inactivation. Although many treatment strategies, such as radiation therapy and chemotherapy, have been proposed to treat anaplastic thyroid carcinoma, they are usually accompanied by concerns such as resistance, which may lead to the lethality of the patient. The emerging nanotechnology-based approaches cater the purposes such as targeted drug delivery and modulation in drug release patterns based on internal or external stimuli, leading to an increase in drug concentration at the site of the action that gives the required therapeutic action as well as modulation in diagnostic intervention with the help of dye property materials. Nanotechnological platforms like liposomes, micelles, dendrimers, exosomes, and various nanoparticles are available and are of high research interest for therapeutic intervention in anaplastic thyroid cancer. The pro gression of the disease can also be traced by using magnetic probes or radio-labeled probes and quantum dots that serve as a diagnostic intervention in anaplastic thyroid cancer.
Insights
Anaplastic thyroid cancer, a deadly disease, can be targeted by nanotechnology for improved drug delivery and diagnostics. Nanoparticles offer new hope for treating this aggressive cancer.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Anaplastic thyroid cancer (ATC) is a rare, aggressive thyroid malignancy responsible for a significant proportion of thyroid cancer deaths.
- ATC arises from alterations in critical cellular pathways, including MAPK, PI3K/AKT/mTOR, ALK, Wnt, and TP53.
- Conventional treatments like chemotherapy and radiation therapy for ATC often face challenges with drug resistance and patient lethality.
Purpose of the Study:
- To explore the potential of nanotechnology-based approaches for the treatment and diagnosis of anaplastic thyroid cancer.
- To highlight how nanotechnological platforms can enhance targeted drug delivery and modulate drug release for improved therapeutic efficacy.
- To discuss the application of nanoprobes for the diagnostic intervention and monitoring of ATC progression.
Main Methods:
- Review of current literature on nanotechnology applications in anaplastic thyroid cancer.
- Analysis of various nanotechnological platforms, including liposomes, micelles, dendrimers, exosomes, and nanoparticles.
- Investigation of diagnostic nanoprobes such as magnetic probes, radio-labeled probes, and quantum dots.
Main Results:
- Nanotechnology enables targeted drug delivery, increasing drug concentration at the tumor site and minimizing systemic toxicity.
- Stimuli-responsive nanocarriers can modulate drug release patterns, optimizing therapeutic outcomes in ATC.
- Nanoparticles and nanoprobes offer promising avenues for both therapeutic intervention and advanced diagnostic imaging in ATC.
Conclusions:
- Nanotechnology presents a promising frontier for overcoming the limitations of conventional therapies in anaplastic thyroid cancer.
- The development of targeted nanodrugs and advanced nanodiagnostics can significantly improve patient outcomes for this aggressive disease.
- Further research into nanotechnological platforms is crucial for realizing their full potential in managing anaplastic thyroid cancer.
